Roles of noncoding RNAs in drug resistance in multiple myeloma |
| |
| Authors: | Jingwen Li Jing Zou Xiaoyue Wan Chunyan Sun Zhangbo Chu Yu Hu |
| |
| Institution: | 1. Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;2. Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Collaborative Innovation Center of Hematology, Huazhong University of Science and Technology, Wuhan, China |
| |
| Abstract: | Despite the administration of new effective drugs in recent years, relapse and drug resistance are still the main obstacles in multiple myeloma (MM) treatment, making MM an incurable disease. To overcome drug resistance in MM, it is critical to understand the underlying mechanisms of malfunctioning gene expression and develop novel targeted therapies. During the past few decades, with the discovery and characterization of noncoding RNAs (ncRNAs), the landscape of dysregulated ncRNAs of cancers as well as their biological and pathobiological functions in tumorigenesis and drug resistance have been recognized. Studies about ncRNAs improved the understanding of variations of drug response among individuals at a level distinguished from genetic polymorphism, and provided with new orientations for targeted therapies. In this review, we will summarize the emerging impact and underlying molecular mechanisms of the most relevant classes of ncRNAs in drug resistance of MM, and discuss the potential as well as strategies of treating ncRNAs as therapeutic targets. |
| |
| Keywords: | drug resistance long noncoding RNA microRNA multiple myeloma signaling pathway |
|
|
